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Editorial 
Right To Life vs. Upjohn 
Mr. W. N. Hubbard, Jr., President of the Upjohn Company, is 
quoted as follows in the December, 1972 issue of The Journal of Re-
productive Medicine: 
"We are confronted with the problem of discrepancy between total 
productivity of the human race as it is now organized and its con· 
sumptive demands. This discrepancy has led to a threatening differ· 
ence between the "have's" and "have·not's." If we are to have each 
human life fulfill its potential, then we will have to reduce this dis· 
crepancy between productivity and consumptive demand. With limited 
resources in an ecology that is subject to harmful alteration, there is 
some doubt about the strategy of only increasing production. There· 
fore, for the first time, the medical profession is involved in the inhibi· 
tion of life and here we look to the most effective and convenient 
means. Considering the pathology of population concentration and the 
futility of trying to keep up with an explosive birth rate by increasing 
productivity alone, the need for limitation of new human life becomes 
persuasive." 
In order to appreciate fully the insidious significance of the previous 
statement, it is important for both physicians and officials of the 
pharmaceutical industry to understand what is behind the current 
widespread boycott of Upjohn products, which is occurring in Catholic 
hospitals all across the United States. The response on the part of the 
Upjohn Company officials to resolutions from numerous Boards of 
Trustees has betrayed an unfortunate propensity to define improperly 
the issues at hand. 
First of all, the Catholic medical community fully comprehends the 
significance and importance of research in prostaglandins. It is some-
what patronizing to be reminded that prostaglandins do have other 
therapeutic potential, even if Prostaglandin F, Alpha is currently ap-
proved by the Food and Drug Administration solely for the indication 
of intra-amniotic injection to induce abortion in the second trimester. 
The therapeutic versatility of prostaglandins is no more relevant to 
the issue at hand than would a statement that table salt also has 
uses beyond saline amniocentesis. 
Likewise, the statement by the Upjohn public relations department 
that the company "takes no position" on abortion entirely begs the 
question. The promotion of an abortifacient drug is not a "non-
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position" even if the drug is less risky to use than hysterotomy and 
salting out. The maternal risks of second trimester abortion are im-
portant, but the uniform fetal mortality of second trimester abortions 
remains unchanged with intra-amniotic prostaglandin installation and 
the deplorable occurrence of previable live births is actually increased. 
The only way to eliminate "avoidable risks" to the mother and the 
unborn child is to ban this barbaric procedure altogether. 
Nevertheless, we cannot insist that every corporate official subscribe 
to the tenets of the Right to Life Movement. What we cannot accept, 
however, is the fact that the chief corporate officer of a major phar-
maceutical company has publicly announced that the company will 
divert part of its research and development effort, however large or 
small, into finding "the most effective and convenient means" of kill-
ing. Mr. Hubbard blandly accepts the propriety of the medical pro-
fession's involvement in "the inhibition of life." His viewpoint may not 
be unique, but it is certainly the first public statement of its type and, 
as such, it must call forth the most vigorous protest from all who de-
plore the current anti-life trend in our society. Mr. Hubbard borrows 
from the Apocalyptic Demographers in suggesting a present population 
crisis demanding lethal solutions. His viewpoint would not be sup-
ported by anything resembling a scientific consensus, especially in this 
country now experiencing the lowest birth rate in its history and a 
growth rate less than zero population growth. Putting aside the merits 
of Mr. Hubbard's population theories, however, one cannot avoid a 
feeling of affront at hearing life-inhibition promoted as a strategy by 
a leading spokesman for one of the life sciences. Those of us in the 
medical profession have every reason to expect that the pharmaceutical 
industry will stand with us in a united front against any encroachment 
on the inviolability of human life notwithstanding any alleged societal 
benefits to be derived from such an encroachment. 
Until such time as the Upjohn Company publicly reasserts its regard 
for the sanctity of life at all stages of life's continuum, every physician 
is urged to form a right conscience and make an informed judgement 
regarding the dispensing of any Upjohn product, either' in his private 
practice or his hospital affiliations, particularly whenever a generically 
equivalent product is available. 
-E. F. D. 
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